Figure 1.

Five-year cumulative incidence of docetaxel (D, solid line) and mitoxantrone (M, dashed line) use from diagnosis among patients presenting with metastatic prostate cancer. The figure shows cumulative incidence for each two-year cohort from 1996 through 2005, inclusive. The cohort intervals were constructed such that the latest interval, for patients diagnosed from 2004 through 2005, had up to five years of potential follow-up (given that Medicare claims through 2008 were used). Cumulative incidence for patients diagnosed in 1995, representing only a single year of diagnoses, is not shown. Five-year cumulative incidence estimates are indicated at the top of each panel.